Redefining Platinum Therapy in Colorectal Cancer

Redefining Platinum Therapy in Colorectal Cancer: How Tumor Retention and Resistance Biology May Shape the Next Generation of Oxaliplatin-Based Treatment

Executive Summary

Colorectal cancer (CRC) is one of the fastest-rising cancer trends globally and has become a major concern within oncology. CRC incidence continues to increase in men and women <50 years and remains one of the most common causes of cancer-related mortality worldwide. Despite significant advances in molecular diagnostics, targeted therapies, and immuno-oncology, platinum-based chemotherapy continues to serve as the foundation of treatment for the majority of patients with metastatic colorectal cancer (mCRC). More than two decades after its introduction, oxaliplatin remains a critical component of frontline regimens such as FOLFOX and CAPOX.

Yet oxaliplatin’s clinical utility is constrained by two persistent challenges: the development of resistance and cumulative neurotoxicity. While many patients initially respond, therapeutic benefit often diminishes as tumors adapt through multiple resistance mechanisms. Simultaneously, chemotherapy-induced peripheral neuropathy (CIPN) frequently forces dose reductions or treatment discontinuation, limiting the duration of effective therapy.

As discussions at ASCO 2026 continue to focus on treatment sequencing, resistance management, and strategies to extend clinical benefit in gastrointestinal malignancies, there is increasing recognition that improving drug delivery and retention may be as important as discovering entirely new molecular targets.

INNOVOTEX’s lead clinical candidate, NOVO-111, was designed around this premise. Rather than replacing platinum therapy, NOVO-111 seeks to enhance and extend its therapeutic potential through a novel Macrocycle Drug Conjugate (MDC) architecture that combines a tumor-localizing expanded porphyrin macrocycle with a lipophilic Pt(IV) oxaliplatin prodrug.

Recent preclinical studies demonstrate that NOVO-111 substantially improves survival outcomes compared with oxaliplatin alone while exhibiting enhanced tolerability and the potential to overcome multiple mechanisms of platinum resistance. These findings suggest a new therapeutic paradigm: one focused not solely on target engagement, but on sustained intratumoral drug retention and exposure.

The Challenge: Platinum Therapy Remains Essential but Imperfect

Oxaliplatin transformed the treatment landscape for colorectal cancer when incorporated into combination regimens such as FOLFOX. Improvements in response rates, progression-free survival, and overall survival established platinum therapy as a cornerstone of care.

However, the underlying biology of metastatic disease continues to limit long-term outcomes.

Tumors evolve under therapeutic pressure. Drug transport pathways become altered. DNA repair mechanisms become upregulated. Cellular detoxification systems become activated. Together, these adaptive processes diminish platinum accumulation within tumor cells and reduce treatment efficacy.

Importantly, platinum resistance rarely results from a single mutation or pathway. Instead, resistance typically emerges through a complex network of biological adaptations, including:

• Reduced cellular uptake of platinum compounds
• Increased drug efflux
• Enhanced DNA repair capacity
• Altered redox biology
• Tumor microenvironment-mediated protection
• Cellular tolerance to platinum-induced DNA damage

This multifactorial nature of resistance helps explain why simply increasing oxaliplatin dose intensity has historically produced limited benefit.

Compounding this challenge is cumulative neurotoxicity. Peripheral neuropathy remains one of the most significant dose-limiting toxicities associated with oxaliplatin. For many patients, treatment discontinuation occurs not because disease progresses, but because toxicity becomes intolerable.

The result is a therapeutic paradox: the drug remains effective, yet patients often cannot stay on treatment long enough to fully realize its benefit.

Beyond Targeting: The Emerging Importance of Tumor Retention and Redox Biology

For more than two decades, oncology innovation has been dominated by one central concept: targeting. From monoclonal antibodies to antibody-drug conjugates (ADCs), bispecific antibodies, and precision therapies, the prevailing strategy has been to identify a tumor-specific marker and use it to direct therapeutic payloads toward cancer cells while sparing healthy tissue.

This approach has transformed patient care and produced important advances across multiple tumor types. However, a growing body of evidence suggests that targeting alone may not be sufficient.

A fundamental challenge remains largely unchanged: a therapeutic agent must first reach the tumor in meaningful concentrations before it can exert a biological effect.

Recent analyses of targeted therapeutics have highlighted a surprising reality. Despite sophisticated targeting mechanisms, less than 1% of administered ADC payload typically reaches solid tumors. Numerous biological barriers—including vascular heterogeneity, elevated interstitial pressure, stromal architecture, antigen variability, and inefficient tissue penetration—limit the amount of active drug ultimately delivered to malignant tissue.

As a result, many targeted therapies face a delivery paradox. They are highly selective for cancer cells but may still deliver only a small fraction of the administered therapeutic payload to the tumor itself.

The question therefore becomes not simply “Can we target the tumor?” but rather “Can we deliver enough drug to the tumor to meaningfully alter disease biology?”

NOVO-111 was developed around a fundamentally different principle.

Rather than relying on antigen recognition, NOVO-111 leverages intrinsic characteristics common to many cancers, particularly alterations in tumor redox biology. Malignant cells frequently exist in a state of oxidative stress characterized by disrupted redox balance, elevated reactive oxygen species, altered mitochondrial function, and increased reducing capacity relative to normal tissues.

The expanded porphyrin macrocycle component of NOVO-111 was specifically designed to exploit these tumor-associated redox conditions. Following preferential accumulation within malignant tissue, the macrocycle becomes selectively retained through redox-dependent mechanisms, creating prolonged intratumoral exposure that is difficult to achieve with conventional targeting approaches.

This distinction is important.

Targeting determines where a drug initially goes.

Retention determines how long it stays.

Ultimately, therapeutic efficacy depends on both.

Preclinical studies have demonstrated that NOVO-111 achieves greater than 12% tumor delivery—more than an order of magnitude higher than the levels typically reported for many targeted payload platforms. This enhanced delivery is coupled with sustained retention within tumor tissue, allowing prolonged intracellular exposure to active platinum species.

The implications are significant. A therapy that consistently delivers and retains substantially more active drug within tumors may be better positioned to overcome resistance mechanisms that emerge when drug concentrations become subtherapeutic. Rather than repeatedly escalating dose intensity, improving intratumoral exposure may provide a more efficient means of enhancing efficacy while reducing systemic toxicity.

This concept represents a broader evolution in oncology drug development. The next generation of therapies may not be defined solely by their ability to recognize cancer cells, but by their ability to achieve sufficient concentration, duration, and persistence within tumors to drive durable responses.

In this context, NOVO-111 represents more than a new platinum compound. It represents a shift from a target-centric paradigm toward a tumor-retention paradigm, where redox biology becomes a mechanism for selective accumulation, sustained exposure, and ultimately improved therapeutic outcomes.

A Different Approach: Improving What Happens After Drug Delivery

The oncology industry has spent the last two decades focused primarily on improving targeting. Antibody-drug conjugates (ADCs), bispecific antibodies, and precision therapies have sought to deliver therapeutics more selectively to cancer cells.

While target selection has transformed oncology, an important question remains:

What happens after a therapeutic agent reaches the tumor?

Drug exposure within tumors is often transient. Penetration may be heterogeneous. Intratumoral concentrations may never reach levels necessary to overcome resistance mechanisms.

NOVO-111 was developed around a different hypothesis:

Improving retention and persistence within tumors may be equally important as improving initial delivery.

The molecule combines two clinically validated components:

1. A tumor-localizing expanded porphyrin macrocycle with a demonstrated history of selective tumor accumulation.
2. A lipophilic Pt(IV) oxaliplatin analogue designed for intracellular activation.

This architecture creates a Macrocycle Drug Conjugate (MDC) capable of selectively accumulating within tumors while delivering sustained platinum exposure directly to malignant cells.

Rather than relying on antigen expression, NOVO-111 leverages intrinsic tumor biology, including altered redox states and metabolic characteristics, to promote preferential retention.

This antigen-independent approach may offer several potential advantages:

• Reduced vulnerability to tumor heterogeneity
• Broader applicability across patient populations
• Improved penetration throughout tumor tissue
• Sustained intracellular drug exposure
• Enhanced ability to overcome resistance mechanisms

Preclinical Evidence: Significant Survival Advantage in Colorectal Cancer Models

Recent colorectal cancer xenograft studies provide compelling evidence supporting the NOVO-111 mechanism.

In these studies, animals treated with NOVO-111 demonstrated substantially improved long-term survival compared with both vehicle control and oxaliplatin-treated cohorts.

Most notably:

• 88% of NOVO-111-treated animals remained alive beyond 80 days
• Only 25% of oxaliplatin-treated animals survived to the same time point

The separation between treatment arms becomes increasingly apparent over time, suggesting durable biological activity rather than merely transient tumor suppression.

Unlike conventional chemotherapy responses that may initially reduce tumor burden but fail to maintain long-term control, NOVO-111 appears to produce sustained survival benefit consistent with prolonged intratumoral activity.

The magnitude of this survival improvement is particularly noteworthy given that oxaliplatin itself remains an active standard-of-care comparator.

The findings suggest that optimizing platinum delivery and retention may generate clinically meaningful improvements without requiring an entirely new cytotoxic mechanism.

Overcoming Resistance Through Tumor Retention

One of the most intriguing aspects of NOVO-111 is its ability to address both multifactorial and transport-defective platinum resistance.

Traditional platinum compounds rely heavily on transport systems that can become dysregulated during tumor evolution. Once transport pathways are altered, intracellular drug concentrations fall, reducing efficacy.

NOVO-111 appears capable of circumventing these limitations.

Preclinical studies have demonstrated:

• Enhanced intracellular platinum accumulation
• Improved tumor payload delivery
• Sustained exposure within malignant tissue
• Activity in models exhibiting platinum resistance

These observations support a broader therapeutic concept emerging across oncology:

The future may not belong exclusively to more potent payloads, but to systems that maintain effective drug concentrations within tumors for longer periods of time.

As resistance mechanisms continue to evolve, retention-based strategies could become increasingly important across multiple therapeutic classes.

Expanding the Therapeutic Window

The ultimate objective of oncology drug development is not simply increasing efficacy or reducing toxicity independently.

It is expanding the therapeutic window.

A therapy capable of delivering more drug to tumors while exposing normal tissues to less drug creates the possibility of achieving both goals simultaneously. Preclinical findings suggest NOVO-111 may move in this direction.

Enhanced tumor delivery has been accompanied by improved tolerability relative to conventional oxaliplatin treatment. These observations raise the possibility that NOVO-111 could reduce the incidence or severity of dose-limiting toxicities, including chemotherapy-induced peripheral neuropathy.

If validated clinically, this could have profound implications.

Patients who remain on therapy longer often achieve greater disease control. Extending treatment duration without increasing toxicity could therefore improve outcomes beyond what is achievable through response rate improvements alone.

This concept aligns closely with one of the most important themes emerging across modern oncology:

Durability matters.

Historically, oncology drug development has focused heavily on response rates and progression-free survival. While these endpoints remain important, there is growing recognition that the durability of therapeutic benefit often determines long-term clinical outcomes.

Cancer is rarely defeated by a single treatment cycle. Most metastatic tumors consist of diverse cellular populations with varying sensitivities to therapy. Initial treatment may eliminate susceptible cells, but residual resistant populations frequently survive and ultimately drive disease progression. As a result, durable disease control requires sustained therapeutic pressure over extended periods of time.

This challenge is particularly relevant in metastatic colorectal cancer, where oxaliplatin-based regimens remain foundational but are often limited by cumulative toxicity and acquired resistance. Many patients discontinue oxaliplatin not because the drug has completely lost efficacy, but because chemotherapy-induced peripheral neuropathy (CIPN) becomes intolerable. Once platinum therapy is discontinued, treatment options become increasingly limited and disease control often diminishes.

The consequence is that the effective duration of therapy frequently becomes a more important determinant of outcome than the initial response itself.

A patient who achieves a modest but durable response over many months may experience greater clinical benefit than a patient who achieves rapid tumor shrinkage followed by early progression. Increasingly, oncologists recognize that maintaining disease control and preserving treatment options over time is central to improving survival.

This concept is reflected across multiple therapeutic modalities. Immunotherapies are valued not solely because they induce responses, but because a subset of patients experience durable remissions. Similarly, targeted therapies are often judged by duration of response as much as objective response rate. Across oncology, durability has emerged as a key measure of therapeutic value.

NOVO-111 was designed with this principle in mind.

By increasing tumor delivery, enhancing intratumoral retention, and providing sustained platinum exposure, NOVO-111 seeks to maintain therapeutic pressure on tumors for longer periods of time. Rather than relying solely on peak drug concentrations, the strategy focuses on prolonging effective intracellular exposure within malignant tissue. This sustained exposure may reduce opportunities for resistant clones to emerge while maintaining antitumor activity over extended intervals.

The preclinical survival data are particularly encouraging in this context. The significant separation observed between NOVO-111 and oxaliplatin-treated animals over time suggests that the benefit may not simply reflect greater initial tumor killing, but rather a more durable suppression of disease progression. Long-term survival differences are often more indicative of sustained biological control than short-term tumor response measurements alone.

Importantly, durability is not solely an efficacy issue—it is also a tolerability issue.

A therapy that delivers more drug to the tumor while reducing systemic exposure has the potential to expand the therapeutic window. Patients may remain on treatment longer, maintain dose intensity, and avoid treatment interruptions that can contribute to disease progression. For platinum therapies, reducing cumulative neurotoxicity could be especially impactful, as CIPN remains one of the primary reasons oxaliplatin is discontinued despite ongoing clinical benefit.

From a healthcare system perspective, durability also carries significant economic implications. Longer-lasting disease control can reduce the need for frequent regimen changes, delay progression to later lines of therapy, decrease hospitalizations, and potentially improve quality of life. In an era increasingly focused on value-based oncology care, therapies that improve durability may create benefits extending far beyond traditional efficacy metrics.

Ultimately, the future of oncology may not belong solely to therapies that produce the deepest responses, but to those that produce the most durable ones. As metastatic cancers increasingly become chronic diseases managed over years rather than months, the ability to sustain treatment benefit may become one of the most important determinants of therapeutic success.

For NOVO-111, the central hypothesis is straightforward: if more platinum reaches the tumor, remains there longer, and can be administered for longer periods because of improved tolerability, then durability itself becomes a therapeutic advantage.

Implications Beyond Colorectal Cancer

While colorectal cancer represents the initial focus, the biological principles underlying NOVO-111 extend far beyond a single indication.

Platinum resistance remains a major challenge across numerous solid tumors, including:

• Ovarian cancer
• Non-small cell lung cancer
• Gastric cancer
• Pancreatic cancer
• Head and neck cancers

Because NOVO-111 does not rely on a specific antigen target, its potential applicability may be substantially broader than many contemporary precision oncology approaches.

This characteristic becomes increasingly relevant as the field confronts the limitations of highly fragmented molecular subpopulations. While precision medicine has produced remarkable advances, it has also created increasingly narrow patient segments.

Tumor-retention strategies may offer a complementary path forward—one capable of benefiting larger populations while still leveraging biologically informed design.

Looking Ahead

The evolution of oncology has often been defined by shifts in perspective.

First came cytotoxic chemotherapy.

Then targeted therapy.

Then immunotherapy.

Today, a new question is emerging:

Can improving drug retention and persistence within tumors fundamentally change therapeutic outcomes?

The preclinical data generated with NOVO-111 suggest the answer may be yes.

By combining selective tumor localization, sustained platinum exposure, enhanced payload delivery, and activity against resistant disease, NOVO-111 represents a new approach to one of oncology’s most established therapeutic classes.

As INNOVOTEX advances toward clinical development, the goal is not to replace the successes of platinum therapy, but to build upon them—transforming a proven mechanism into a more durable, better tolerated, and potentially more effective treatment platform.

If successful, NOVO-111 may represent more than a new drug candidate.

It may represent a new way of thinking about how cancer therapies achieve durable clinical benefit.